BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

Company Overview - BrainsWay Ltd. is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders [3] - The company utilizes its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives [3] - BrainsWay is the first and only TMS company to obtain three FDA-cleared indications, which include major depressive disorder, obsessive-compulsive disorder, and smoking addiction [3] Upcoming Financial Results - BrainsWay will report its second quarter 2024 financial results and operational highlights on August 6, 2024, before the U.S. financial markets open [1] - A conference call and webcast will be held at 8:30 AM Eastern Time to discuss the results and provide updates on business operations [1][2] Clinical and Operational Focus - The company is dedicated to advancing neuroscience and building on its clinical evidence through ongoing clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders [3] - BrainsWay aims to increase global awareness and access to Deep TMS treatments [3]